Effect of Prolonged Fasting Time on Gastric Residual Volume in Patients Taking GLP1 Receptor Agonists

Mayo Clinic

Status: Enrolling

Conditions: GLP1-R-related Disease; Upper Endoscopy

Treatments: Other: Modified Fasting Guidelines

Study type: Interventional

Funder types: Other

Identifiers

NCT07006142

23-013192

Details and patient eligibility

About

The aim of this study is to determine whether a modified fasting protocol can reduce the potential risk of aspiration for patients currently prescribed GLP1-RAs.

Full description

The overall objective of this project is to identify a reasonable means by which patients on GLP1-RAs can be safely cared for in the perioperative period that can be agreed upon by all groups involved in perioperative patient care. This will be assessed in patients undergoing upper endoscopy specifically since assessment of gastric contents would be minimally invasive for this patient population receiving anesthetic care.

Enrollment: 150 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients undergoing elective upper endoscopy with gastroenterology team

Exclusion criteria

• Urgent or emergent procedure
• Inclusion of colonoscopy or antegrade small bowel enteroscopy in planned procedure
• Upper GI barium study performed in past 24 hours.
• Gastroparesis
• Achalasia
• Pancreatitis
• Use of outpatient pro-motility medications
• Patient refusal
• Inability for patient to provide own consent

Trial design

Primary purpose: Prevention

Allocation: N/A

Interventional model: Single Group Assignment

Masking: Single Blind

---

150 participants in 3 patient groups

Normal fasting guidelines and not taking GLP1-RAs

No Intervention group

Description:

Patients who are not taking GLP1 RAs (Receptor Agonists) and who will abide by the normal fasting guidelines

Normal fasting guidelines with GLP1-RAs

No Intervention group

Description:

Patients who are taking GLP1 RAs (Receptor Agonists) for either diabetes or weight loss management who will abide by normal fasting guidelines

Modified fasting guidelines with GLP1-RAs

Experimental group

Description:

Patients who are prescribed and taking GLP1 RAs (Receptor Agonists) for either diabetes or weight loss management who follow the modified fasting guidelines. Modified fasting consists of a full-liquid diet 48 hours prior to the procedures, clear liquid diet 24 hours prior to their procedure, and nothing by mouth (NPO) after midnight on the day of their procedure.

Treatment:

Other: Modified Fasting Guidelines